Company profile
Amexdrug Corporation
OTC: AXRX · Healthcare · Drug Manufacturers - Specialty & Generic
#757 of 1,418 Healthcare companies by revenue30th-percentile growth
EA Score
69BFH 79DQ —GM 51SS 43
v0.1 · 45/100 weight · provisional
↑ growth stability, return on assets · ↓ market scale, 3-yr revenue growth
Methodology →Revenue TTM
$2.9M
Rev growth YoY (TTM)
-10.5%
Net income (FY)
$40.3k
Employees
9
as of 2026-08-03
Market cap
$33.9k
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.9M$2.9M2025
Net income$40.3k$40.3k2025
Operating income$136.8k$136.8k2025
Total assets$2.5M$2.5M2025
Liabilities$717.9k$717.9k2025
Equity$1.8M$1.8M2025
Revenue trend
FY2017 – FY2025 · USD
FY17
FY18
FY19
FY20
FY21
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Amexdrug Corporation’s revenue?
Amexdrug Corporation booked $2.9M in FY2025 revenue, contracting 15% year over year — slower than 70% of Healthcare companies we track, at a 1.4% net margin.
Peers · Healthcare
PeakBirch Commerce Inc.——Protara Therapeutics, Inc.43DOSR Holdings, Inc.34DRadient Technologies Inc.——SCWorx Corp.49DStemtech Corporation26DNeighbors
Los Angeles →Key facts
CEOJack Amin
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCommerce, CA
ExchangeOTC: AXRX
Employees9
IPO date2001-03-29
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.